Comparative in Vitro Activities of GSK2251052, a novel boron-containing leucyl-tRNA synthetase inhibitor, against 916 anaerobic organisms

Abstract

We studied the comparative in vitro activity of GSK2251052, a novel boron leucyl-tRNA synthetase inhibitor, against 916 clinical anaerobic isolates using CLSI methods. The GSK MIC50/MIC90 for all isolates tested were 2 and 4 μ/ml, and the MIC90s against 302 Bacteroides fragilis and Bacteroides thetaiotaomicron strains were 4 and 8 μ/ml, respectively. All Clostridium perfringens strains had GSK2251052 MICs of>32 μ/ml. There was no relationship between increased MICs for any other antibiotics and that of GSK2251052. Copyright © 2013, American Society for Microbiology. All Rights Reserved.